Publications
- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatmentPublication without faculty affiliation
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | First Faculty of Medicine
- TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes2016 | First Faculty of Medicine
- Application of interphase fluorescence in situ hybridisation for the analysis of CD34+ cells in peripheral blood of patients with myelodysplastic syndromes +12016 | First Faculty of Medicine
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide2015 | Faculty of Science
- Case report: (non)chelated, poly-transfused patient with 5q minus syndrome2015 | First Faculty of Medicine
- Are we justified to classify patients with two unrelated clones with del(5q) and trisomy 8 as a subgroup of myelodysplastic syndrome of the type of 5q-syndrome?2014 | First Faculty of Medicine
- Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis2014 | First Faculty of Medicine
- Významný recentní přehled o klinice, patogenezi a terapii MDS s del(5q) lenalidomidem2014 | First Faculty of Medicine
Loading network view...